DoD Rare Cancers, Idea Development Award | HT942525RCRPIDA

Opportunity Information: Apply for HT942525RCRPIDA

The FY25 DoD Rare Cancers Research Program (RCRP) Idea Development Award (IDA) is a discretionary research grant from the Department of the Army, administered through the U.S. Army Medical Research Acquisition Activity (USAMRAA). It is designed to push forward new, early-stage ideas in rare cancer research, especially concepts that are not yet fully mature but could generate meaningful data and open up new lines of investigation. The overall emphasis is on innovation that can translate into clear potential benefit for rare cancer patients and the broader rare cancer community.

This award is specifically positioned for projects that are still developing, where key questions may not be fully answered yet, but where the proposed work is likely to produce impactful, decision-shaping results. A notable feature is that applications are encouraged to include an exploratory aim or a sub-aim. In practice, this means applicants can build in a discovery-driven component, such as an initial screen, feasibility test, or early mechanistic probe that helps justify and inform later, more hypothesis-driven work. The program is signaling that it understands the realities of rare cancer research, where basic groundwork and enabling experiments are often required before a project can move into more definitive studies.

At the same time, the IDA is not intended to be purely speculative. Preliminary data are required, along with a disease-specific rationale. However, the program allows flexibility in how that preliminary evidence is assembled: the data do not have to come directly from studies in the exact rare cancer type or subtype being proposed. That can be important for rare diseases where samples, models, or prior datasets may be limited. Applicants can leverage related systems or adjacent evidence, as long as they convincingly connect the preliminary findings to the rare cancer question and explain why the approach is likely to matter for that patient population.

Impact is a central review lens. The proposed research should have high potential to change understanding, create new investigative directions, or meaningfully advance progress against rare cancers. Successful proposals will typically make a strong case for why the idea is important now, what key bottleneck it addresses, and how the expected outputs could accelerate future translational work, improve biology-driven stratification, or otherwise contribute to outcomes that matter to patients.

Administratively, the opportunity is listed under Funding Opportunity Number HT942525RCRPIDA and CFDA 12.420, within the Science and Technology and other Research and Development category. Eligibility is described as unrestricted, indicating a broad applicant pool (subject to the full funding announcement terms). The application closing date is October 6, 2025, and the program expects to make about 14 awards.

One important update for FY25 is how budgets are framed. Funding limits are now presented as total cost limits, meaning the cap includes both direct and indirect costs combined. This matters for planning because institutions with higher indirect cost rates will need to account for that within the same overall ceiling, which can reduce the amount available for direct research expenses compared to mechanisms that cap only direct costs.

In short, this is a DoD rare cancers grant mechanism aimed at supporting promising, early-stage ideas with enough preliminary support to be credible, while still leaving room for exploratory, discovery-driven work. The program is looking for projects that can generate influential data and set the stage for bigger advances in rare cancer research, with a clear throughline to patient impact.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Rare Cancers, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2025-05-01.
• Applicants must submit their applications by 2025-10-06. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 14 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942525RCRPIDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: